APLMW (Apollomics) Median PS Value: $0.00 (As of Jun. 24, 2026)


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.01
! 5 Warning Signs
View Full Analysis

What is Apollomics Median PS Value?

Apollomics APLMW -7.91% 31 Median PS Value is $0.00 as of Jun. 24, 2026. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 276 Biotechnology companies, Apollomics ranks worse than 362318.48% on this metric.

This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Apollomics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.095. Apollomics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2026-06-24), Apollomics's share price is $0.0139. Apollomics's Median PS Value is $0.00. Therefore, Apollomics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Apollomics's Median PS Value or its related term are showing as below:

APLMW's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.63
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Apollomics  (NAS:APLMW) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Apollomics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.0139/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollomics Median PS Value Related Terms


Apollomics Median PS Value Historical Data

* Premium members only.

The historical data trend for Apollomics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics Median PS Value Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Median PS Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

APLMW vs TVRD, PLRZ, LSTA: Median PS Value Comparison

For the Biotechnology subindustry, Apollomics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollomics Price-to-Median-PS-Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Apollomics's Price-to-Median-PS-Value falls into.


APLMW
31GF Score
Apollomics Inc APLMW
Median PS Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Median PS Value Calculation

Apollomics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.095*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apollomics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.095.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Median PS Value →
What does a Median PS Value of $0.00 mean?
Apollomics (APLMW) has a Median PS Value of $0.00 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Apollomics and its competitors. According to the industry distribution chart, Apollomics ranks #999999 out of 276 companies in the Biotechnology industry.
Is Apollomics' Median PS Value too high?
Apollomics' current Median PS Value is $0.00. Based on the distribution chart, Apollomics ranks #999999 out of 276 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Median PS Value compare to TVRD and PLRZ?
According to the Biotechnology industry distribution chart, Apollomics ranks #999999 out of 276 companies for Median PS Value. This places Apollomics in the lower half of its industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Apollomics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apollomics's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current Median PS Value of $0.00. The current Median PS Value is $0.00. Apollomics' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Apollomics (APLMW), the current Median PS Value is $0.00 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price